Tesaro (TSRO) News Today

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Stock Analysis

Source

Source	Headline
	Keval Desai's Net Worth benzinga.com - February 22 at 2:15 PM
	Tesaro (TSRO) Stock Slumps on Public Offering, Leerink Lifts Price Target thestreet.com - September 14 at 3:56 PM
	Analysts Holding As Pfizer Waits On Two Phase 3 Studies (TSRO) marketbeat.com - February 24 at 9:05 AM
	Dr. Marc Siegel Explains Why Tesaro (TSRO) Cancer Drug Is a Big Deal thestreet.com - January 3 at 11:59 PM
	Immunotherapy Drugs Market Worth $475+ Billion, Globally, by 2028 at 14+% CAGR \| The Insight Partners - PR Newswire prnewswire.com - October 18 at 2:48 AM
	AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials - Yahoo Finance finance.yahoo.com - October 5 at 5:30 PM
	ANAPTYSBIO, INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com marketscreener.com - September 12 at 6:56 PM
	Day One Appoints Garry Nicholson as Chairman of the Board of Directors - Yahoo Finance finance.yahoo.com - September 12 at 6:56 PM
	GlaxoSmithKline : GSK to highlight the latest advances in cancer research from across its portfolio and pipeline at ESMO - Marketscreener.com marketscreener.com - September 1 at 2:35 AM
	North America oncology market value to cross USD 246 billion by 2028 - GlobeNewswire globenewswire.com - August 9 at 3:39 PM
	Global TIM3 Inhibitors Drug Clinical Trials & Market Opportunities Report 2022: Market to Surpass $1 Billion by 2028, Driven by the First Drug Approval Expected to be Launched by 2024 - Yahoo Finance finance.yahoo.com - August 8 at 6:44 PM
	TIM3 Inhibitors Drug Clinical Trials Research Report 2022: Insight on Emerging TIM3 Inhibitors in Development As Monotherapy & Combination Therapy - PR Newswire prnewswire.com - August 6 at 12:11 AM
	TIM3 Inhibitors Drug Clinical Trials Research Report 2022: Insight on Emerging TIM3 Inhibitors in Development As Monotherapy & Combination Therapy - Yahoo Finance finance.yahoo.com - August 5 at 1:36 PM
	TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insights Report 2022-2028 - ResearchAndMarkets.com - Business Wire businesswire.com - August 4 at 7:33 AM
	TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 - Yahoo Finance finance.yahoo.com - July 21 at 1:23 PM
	TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 - GlobeNewswire globenewswire.com - July 21 at 8:23 AM
	Anti TIM3 Inhibitors Drugs Antibody Clinical Trials Market Report 2028 - GlobeNewswire globenewswire.com - July 20 at 11:06 AM
	Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Insights \| DelveInsight - GlobeNewswire globenewswire.com - July 11 at 3:37 PM
	Mary Lynne Hedley Elected to Lilly Board of Directors - GuruFocus.com gurufocus.com - June 25 at 7:03 PM
	Xilio Therapeutics (XLO) Announces Promotion of Martin Huber, MD, to President - StreetInsider.com streetinsider.com - June 16 at 10:54 AM
	Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA - PR Newswire prnewswire.com - May 31 at 10:37 AM
	Mary Lynne Hedley Elected to Lilly Board of Directors - Yahoo Finance finance.yahoo.com - May 8 at 9:34 AM
	Mary Lynne Hedley Elected to Lilly Board of Directors - StreetInsider.com streetinsider.com - May 7 at 12:26 PM
	Eli Lilly & Co. (LLY) Appoints Mary Lynne Hedley to its Board - StreetInsider.com streetinsider.com - May 6 at 3:34 PM
	Mary Lynne Hedley Elected to Lilly Board of Directors - PR Newswire prnewswire.com - May 6 at 3:34 PM
	Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer - Business Wire businesswire.com - April 28 at 2:23 PM
	GSK Agrees to Buy Sierra Oncology for $1.9 Billion in Cash - Bloomberg bloomberg.com - April 13 at 4:16 AM
	Del. Justices Uphold Toss Of Suit Over Tesaro's $5.1B Sale - Law360 law360.com - April 9 at 12:11 AM
	Sofinnova Investments Announces the Addition of Dr. Chris Carpenter as Executive Partner - Business Wire businesswire.com - April 7 at 1:43 AM
	3 CEOs to Invest In - Nasdaq nasdaq.com - April 1 at 10:14 PM
	Clovis Oncology: Forging A Fresh Perspective - Seeking Alpha seekingalpha.com - March 31 at 8:43 PM
	Tesaro Sale Flaws Justify Case Remand, Del. Justices Told - Law360 law360.com - March 30 at 5:10 PM
	Global Ovarian Cancer Drugs Market to 2031 - Featuring AstraZeneca, Roche and Tesaro Among Others - Yahoo Finance finance.yahoo.com - March 29 at 6:05 AM
	$3.25 Billion Worldwide Ovarian Cancer Drugs Industry 2022 - Identify Growth Segments for Investment - ResearchAndMarkets.com - Yahoo Finance finance.yahoo.com - March 28 at 7:08 AM
	Ovarian Cancer Drugs Global Market Report 2022 - Yahoo Finance finance.yahoo.com - March 16 at 9:37 AM
	EPIZYME, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com marketscreener.com - March 15 at 8:31 AM
	Zai Lab: Shares Are Cheap, But Not Without Reason - Seeking Alpha seekingalpha.com - March 9 at 1:23 AM
	Catamaran Bio Announces Appointment of Michael DeRidder, PhD, as Senior Vice President, Corporate Strategy and New Product Planning - Business Wire businesswire.com - February 28 at 11:04 AM
	Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castrati - PRNewswire prnewswire.com - February 14 at 5:34 PM
	Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers - PRNewswire prnewswire.com - February 1 at 9:15 AM
	Cancer Supportive Care Drugs Market to Reach $24.40 Bn, Globally, by 2030 at 2.2% CAGR: Allied Market Research - PRNewswire prnewswire.com - January 20 at 9:36 AM
	Global Pharma and Biotech Preclinical Stage Partnering Deals Directory 2021: Comprehensive Access to Deals and Contract Documents for Over 2,400 Deals - Yahoo Finance finance.yahoo.com - January 15 at 5:53 PM
	Global Pharma and Biotech Preclinical Stage Partnering Deals Directory 2021 - GlobeNewswire globenewswire.com - January 14 at 5:13 PM
	Women's Health Therapeutics Market Report Up to 2031: Visiongain Research Inc - GlobeNewswire globenewswire.com - January 12 at 10:20 AM
	Sleep Aids Market is expected to register a CAGR of 4.5% during the forecast period (2021-2031) - Benzing - Benzinga benzinga.com - December 3 at 8:14 AM
	Poly (ADP-Ribose) Polymerase Inhibitors Pipeline Research Report 2021: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com - Yahoo Finance finance.yahoo.com - December 2 at 3:16 PM
	Poly (ADP-Ribose) Polymerase Inhibitors Pipeline Research Report 2021: Comprehensive Insights About 20+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com - Business Wire businesswire.com - December 1 at 1:23 PM
	4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio - Nasdaq nasdaq.com - November 16 at 12:48 PM
	ACADIA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - marketscreener.com marketscreener.com - November 5 at 6:18 PM
	NEA Welcomes Veteran Life Sciences Investor Michele Park as Partner on Its Healthcare Investing Team - StreetInsider.com streetinsider.com - November 4 at 3:54 PM

Get Tesaro News Delivered to You Automatically

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

TSRO Media Mentions By Week

TSRO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TSRO
News Sentiment
▼
0.00

0.39
▲
Average
Medical
News Sentiment

TSRO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TSRO Articles
This Week
▼
0

0
▲
TSRO Articles
Average Week

Get Tesaro News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:TSRO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tesaro (TSRO) News Today

TSRO Media Mentions By Week

TSRO Media Sentiment

TSRO News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info